000186237 001__ 186237
000186237 005__ 20240229145739.0
000186237 0247_ $$2doi$$a10.3390/cancers14235907
000186237 0247_ $$2pmid$$apmid:36497389
000186237 0247_ $$2altmetric$$aaltmetric:139461379
000186237 037__ $$aDKFZ-2022-03034
000186237 041__ $$aEnglish
000186237 082__ $$a610
000186237 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000186237 245__ $$aIncidence, Mortality and Survival Trends in Breast Cancers Coincident with Introduction of Mammography in the Nordic Countries.
000186237 260__ $$aBasel$$bMDPI$$c2022
000186237 3367_ $$2DRIVER$$aarticle
000186237 3367_ $$2DataCite$$aOutput Types/Journal article
000186237 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1670857932_24789
000186237 3367_ $$2BibTeX$$aARTICLE
000186237 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186237 3367_ $$00$$2EndNote$$aJournal Article
000186237 500__ $$a#EA:C020#LA:B062#
000186237 520__ $$aSurvival in female breast cancers has generally improved but the relative contribution of early detection or treatment in this positive development is not known. Our aim was to assess the possible role of national mammography screening programs in survival improvement. Such screening has been offered to women, usually at 50-69 years of age, in Finland and Sweden since the 1980s and in Denmark and Norway since the 1990s. Participation rates have been high, ranging from 60% to 90%. We analyzed incidence and mortality changes and relative 5- and 10-year survival trends in breast cancer as novel measures in these countries using the NORDCAN database. Survival trends were compared in age groups of women who were screened to those who were not screened. We observed a relative survival advantage in 5-year and 10-year survival in the screened age groups after the period of national mammography screening was in place and this was consistent in each country. Timing and age-specific targeting of the improvements suggest that mammography may have contributed to the survival benefits. However, as we had no individual data on women who used the service, more detailed studies are needed to confirm the suggested survival advantage, particularly concerning mortality in stage-specific breast cancer.
000186237 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000186237 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186237 650_7 $$2Other$$acancer control
000186237 650_7 $$2Other$$amammography
000186237 650_7 $$2Other$$aperiodic survival
000186237 650_7 $$2Other$$atreatment
000186237 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$eLast author$$udkfz
000186237 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14235907$$gVol. 14, no. 23, p. 5907 -$$n23$$p5907$$tCancers$$v14$$x2072-6694$$y2022
000186237 909CO $$ooai:inrepo02.dkfz.de:186237$$pVDB
000186237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000186237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000186237 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000186237 9141_ $$y2022
000186237 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000186237 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000186237 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000186237 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000186237 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000186237 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000186237 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000186237 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000186237 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000186237 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000186237 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000186237 980__ $$ajournal
000186237 980__ $$aVDB
000186237 980__ $$aI:(DE-He78)C020-20160331
000186237 980__ $$aI:(DE-He78)B062-20160331
000186237 980__ $$aI:(DE-He78)HD01-20160331
000186237 980__ $$aUNRESTRICTED